Genetic testing

Global Prenatal Testing Market Report 2024: Historical Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024
Baby, Maternity, Health, Consumer, Other Health, Insight, Noninvasive prenatal testing, Pregnancy, DSM-IV codes, Research, Genetic testing, Labcorp, Government, NIPT, Amniocentesis, ESG, Thermo Fisher Scientific, Maternal death, Chromosome, Illumina, Inc., Biomarker

The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The scope of the prenatal testing market is extensive and continually evolving, reflecting the dynamic landscape of technologies and methodologies employed to assess fetal health during pregnancy.
  • This market is characterized by its global reach, with varying levels of adoption and accessibility across different regions.
  • The report covers geographic regions in detail, so companies interested in expanding their geographic reach will also find this helpful study.

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Health, Clinical Trials, Health Technology, Oncology, Breast cancer, Neoplasm, Patient, Cancer, NTRA, HER2, Woman, MRD, RFS, Recurrence, MD, Doctor of Philosophy, OS, JCO, Genetic testing, Imperial College London, DNA, Plasma, Central Statistics Office (India), Medical imaging

The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS).

Key Points: 
  • The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS).
  • Patients were followed for up to 12 years after surgery and adjuvant chemotherapy, with blood samples collected semi-annually and then analyzed using Signatera.
  • In a multivariate analysis, ctDNA status was the most significant factor associated with RFS and OS.
  • “The findings also bolster the evidence for long-term monitoring of high-risk breast cancer patients, who often face late recurrences.”

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
Saturday, May 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024

Retrieved on: 
Friday, May 3, 2024
AMD, Patient, Abstract (summary), Research, Johnson & Johnson, Collection, Paratriathlon, Abstract, Development, Genetic testing, Retina, Algorithm, Geographic atrophy, Diagnosis, Biomarker, Annual general meeting, ARVO, IRD, Pharmaceutical industry

RARITAN, N.J., May 3, 2024 /PRNewswire/ -- Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The Company's two oral presentations will include one highlighting a real-world analysis on the economic value of early genetic testing in patients with inherited retinal diseases (IRDs), a group of rare eye disorders that can lead to serious vision impairment (Abstract #2154), and the second evaluating the role of automatic deep-learning based algorithms to measure precursors of geographic atrophy (GA), a late-stage and severe form of age-related macular degeneration (AMD) (Abstract #2770).1,2

Key Points: 
  • Johnson & Johnson to debut first-of-its-kind EYE-RD Global Registry, aiming to bridge knowledge gaps for inherited retinal diseases
    RARITAN, N.J., May 3, 2024 /PRNewswire/ -- Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024.
  • "At Johnson & Johnson, we are committed to preserving vision, harnessing the best science to find solutions for those living with blinding retinal diseases," said Hideo Makimura, M.D., Ph.D., Vice President and Global Head, Specialty Ophthalmology Research and Development, Johnson & Johnson Innovative Medicine.
  • "These data at ARVO 2024 showcase our commitment to bringing innovative new therapies that preserve and restore vision for patients worldwide."
  • A complete listing of the Company-sponsored abstracts being featured at the ARVO Annual Meeting is provided below.

May is International 5p- Syndrome (Cri du Chat) Syndrome Awareness Month

Retrieved on: 
Friday, May 3, 2024
Education, Society, International, Syndrome, Social media, Perseverance, Happiness, Life, Genetic testing, Patient, Campaign, Chromosome, Quality of life, Drink, Organization, Disability

LAKEWOOD, Calif., May 2, 2024 /PRNewswire-PRWeb/ -- The 5p- Society of North America, along with families and support organizations from over 95 countries, are bringing awareness of 5p Deletion Syndrome also known as 5p Minus (5p-) Syndrome. Over sixty (60) years ago, Dr. Jerome Lejeune discovered this genetic condition by noticing a similar characteristic in several patients that he had been observing of a high pitched "cat-like sound" vocalization. After doing genetic testing on these patients, he realized the connection is caused by a permanent deletion on the "p" arm of the 5th chromosome. The 2024 awareness campaign celebrates these unique individuals by raising awareness around the world through education and community events, such the "Faces of 5p-"campaign, our "Stripy Socks" campaign, as well as a "Virtual 5K for 5p-" event and family regional gatherings.

Key Points: 
  • Celebrating the amazing and unique individuals with 5p- Syndrome throughout the month of May by spreading awareness around the world.
  • LAKEWOOD, Calif., May 2, 2024 /PRNewswire-PRWeb/ -- The 5p- Society of North America, along with families and support organizations from over 95 countries, are bringing awareness of 5p Deletion Syndrome also known as 5p Minus (5p-) Syndrome.
  • In an ongoing effort to raise awareness, members and supporters are encouraged to participate in events throughout the month.
  • * Virtual 5k for 5p-, to raise awareness and money for programs that benefit the 5p Deletion Syndrome community.

Double Helix Deception: The Return of Genetic Testing Scams in Medicare Fraud

Retrieved on: 
Thursday, May 2, 2024
Alzheimer's disease, Roger Hawkins (drummer), Cancer, Senior Medicare Patrols, Genetic testing, Confusion, DNA, Caregiver, Medicare, SMP, SMPS, Fraud, Pharmaceutical industry

WASHINGTON, May 2, 2024 /PRNewswire/ -- One of the biggest scams targeting Medicare beneficiaries in the last decade has been the genetic testing scam.

Key Points: 
  • WASHINGTON, May 2, 2024 /PRNewswire/ -- One of the biggest scams targeting Medicare beneficiaries in the last decade has been the genetic testing scam.
  • Recently, the Senior Medicare Patrol (SMP) has seen an increase in genetic testing complaints.
  • Across the nation, genetic testing company representatives are offering "free" genetic tests, also referred to as DNA screenings, cancer screenings, and hereditary testing, in exchange for the beneficiaries' Medicare numbers.
  • The SMP has also received reports of genetic testing claims on Medicare statements when the beneficiaries never received any contact about genetic testing.

FutureBridge Releases Tumor Report on the Future of NSCLC Treatment and Evolving Trends

Retrieved on: 
Thursday, May 2, 2024
Oncology, Collaboration, Cell, Research, Genetic testing, Intelligence, Consultant, Lung cancer, Gene, Biomarker, NSCLC

MUMBAI, India, May 2, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, tracks the future of therapies and related trends from a 1-to-25-year perspective and introduces its insightful report, "Future of NSCLC Treatment & Evolving Trends".

Key Points: 
  • MUMBAI, India, May 2, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, tracks the future of therapies and related trends from a 1-to-25-year perspective and introduces its insightful report, "Future of NSCLC Treatment & Evolving Trends".
  • This report is based on its proprietary methodology and combination of human and artificial intelligence, exploring transformative signals shaping the Oncology market.
  • For a more in-depth understanding of NSCLC's evolving landscape and innovations, request our syndicated report and a complimentary sample here .
  • Experience firsthand FutureBridge's commitment to excellence, meticulous analysis, and comprehensive coverage of early-stage NSCLC in our insightful webinar .

FutureBridge Releases Tumor Report on the Future of NSCLC Treatment and Evolving Trends

Retrieved on: 
Thursday, May 2, 2024
Oncology, Collaboration, Cell, Research, Genetic testing, Intelligence, Consultant, Lung cancer, Gene, Biomarker, NSCLC

MUMBAI, India, May 2, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, tracks the future of therapies and related trends from a 1-to-25-year perspective and introduces its insightful report, "Future of NSCLC Treatment & Evolving Trends".

Key Points: 
  • MUMBAI, India, May 2, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, tracks the future of therapies and related trends from a 1-to-25-year perspective and introduces its insightful report, "Future of NSCLC Treatment & Evolving Trends".
  • This report is based on its proprietary methodology and combination of human and artificial intelligence, exploring transformative signals shaping the Oncology market.
  • For a more in-depth understanding of NSCLC's evolving landscape and innovations, request our syndicated report and a complimentary sample here .
  • Experience firsthand FutureBridge's commitment to excellence, meticulous analysis, and comprehensive coverage of early-stage NSCLC in our insightful webinar .

Newsweek Names CancerIQ One of the World's Best Digital Health Companies

Retrieved on: 
Thursday, May 2, 2024
Statista, Mortality, Genetics, Genomics, Risk, Genetic testing, Digital, Digital health, Biomarker, Mobile phone

CHICAGO, May 2, 2024 /PRNewswire-PRWeb/ -- CancerIQ, a best-in-class cancer-focused precision health platform, today announced it was recognized by Newsweek and Statista as one of the World's Best Digital Health Companies in 2024. CancerIQ was named a leader in data analytics, highlighting the powerful technology behind the company's end-to-end solution for precision cancer prevention, early detection and treatment.

Key Points: 
  • CancerIQ, a best-in-class cancer-focused precision health platform, today announced it was recognized by Newsweek and Statista as one of the World's Best Digital Health Companies in 2024.
  • CHICAGO, May 2, 2024 /PRNewswire-PRWeb/ -- CancerIQ , a best-in-class cancer-focused precision health platform, today announced it was recognized by Newsweek and Statista as one of the World's Best Digital Health Companies in 2024.
  • "Being recognized as one of the best digital health companies by Newsweek is yet another validation that our efforts are making an impact," said Feyi Ayodele, founder and CEO of CancerIQ.
  • Being recognized as one of the best digital health companies by Newsweek is yet another validation that our efforts are making an impact," said Feyi Ayodele, founder and CEO of CancerIQ.

PreludeDx Welcomes Dr. Pat Whitworth as Chief Medical Officer to Drive Expansion of Precision Diagnostics

Retrieved on: 
Thursday, May 2, 2024
MD Anderson Cancer Center, University, Author, American College, Cell biology, Research, Associate professor, Surgical oncology, Growth, Genetic testing, Principal, Society, NCI, Medicine, Committee, Breast cancer, Medical imaging

LAGUNA HILLS, Calif., May 2, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced the appointment of Dr. Pat Whitworth as its new Chief Medical Officer.

Key Points: 
  • LAGUNA HILLS, Calif., May 2, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced the appointment of Dr. Pat Whitworth as its new Chief Medical Officer.
  • Dr. Whitworth's extensive clinical and research expertise across the multiple stages of the breast cancer patient journey will bring invaluable leadership as PreludeDx expands its diagnostic portfolio.
  • "I'm thrilled to join the PreludeDx team during this important growth period and contribute to the mission of improving breast cancer outcomes," said Dr. Whitworth.
  • "The company's commitment to personalized medicine with innovative tests like DCISionRT and patient-centered care aligns perfectly with my values."